Compare IESC & KRYS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IESC | KRYS |
|---|---|---|
| Founded | 1997 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Engineering & Construction | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.8B | 7.8B |
| IPO Year | 1997 | 2017 |
| Metric | IESC | KRYS |
|---|---|---|
| Price | $485.26 | $264.14 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 11 |
| Target Price | ★ $458.00 | $297.60 |
| AVG Volume (30 Days) | 170.2K | ★ 231.7K |
| Earning Date | 05-01-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 51.87 | ★ 128.00 |
| EPS | 4.51 | ★ 6.84 |
| Revenue | ★ $3,371,468,000.00 | $389,130,000.00 |
| Revenue This Year | $22.20 | $39.88 |
| Revenue Next Year | $14.88 | $34.38 |
| P/E Ratio | $117.22 | ★ $39.26 |
| Revenue Growth | 16.89 | ★ 33.94 |
| 52 Week Low | $164.12 | $123.03 |
| 52 Week High | $546.35 | $298.30 |
| Indicator | IESC | KRYS |
|---|---|---|
| Relative Strength Index (RSI) | 48.34 | 51.81 |
| Support Level | $378.25 | $254.53 |
| Resistance Level | $493.66 | $263.75 |
| Average True Range (ATR) | 27.20 | 8.71 |
| MACD | 2.45 | 1.48 |
| Stochastic Oscillator | 43.75 | 60.76 |
IES Holdings Inc owns and manages subsidiaries that design and installs integrated electrical and technology systems and provide infrastructure products and services. It has four business segments; Communications, Residential, Infrastructure Solutions, and Commercial & Industrial. The majority of the revenue for the company is generated from its Residential segment in which the company provides electrical installation services for single-family housing and multi-family apartment complexes, as well as heating, ventilation, and air conditioning (HVAC) and plumbing installation services. This segment also provides services for installing residential solar power, both for new construction and existing residences.
Krystal Biotech Inc is engaged in the healthcare sector in the United States. It is focused on the development of easy-to-use, redosable gene therapies to improve the lives of patients living with debilitating diseases. The company used its proprietary gene therapy platform, STAR-D to develop treatments for rare or orphan dermatological indications caused by the absence of or a mutation in a single gene. It plans to leverage its platform to expand its pipeline to include other dermatological indications in the future. The company has one operating segment, which is the business of developing and commercializing pharmaceutical products.